FindTrial
Sign In

Study on the correlation between non-response to infliximab treatment and intestinal flora, oral flora and plasma metabolites in patients with inflammatory bowel disease

Study on the correlation between non-response to infliximab treatment and intestinal flora, oral flora and plasma metabolites in patients with inflammatory bowel disease

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500096107
Enrollment
Unknown
Registered
2025-01-17
Start date
2025-02-01
Completion date
Unknown
Last updated
2025-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Abdominal pain

Interventions

Infliximab response group:None
Healthy people group:None
Digestive disease group with non-inflammatory bowel disease:None

Sponsors

Southern Medical University Southern Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Voluntarily sign the informed consent form; 2. Age> = 18 (in principle, not self-modification); 3. Gender: according to the provisions of the program; 4. Patients diagnosed with inflammatory bowel disease based on internationally recognized Lennard-Jones criteria; 5. Patients who need to be treated with infliximab according to the judgment of the treating doctor.

Exclusion criteria

Exclusion criteria: 1.Those who are judged by the researcher to be unsuitable to participate in this study

Design outcomes

Primary

MeasureTime frame
Metagenome;Metabolomics;—

Countries

China

Contacts

Public ContactChen Ye

Southern Medical University Southern Hospital

yechen41570@gmail.com+86 20 61641543

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026